Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | XBP1 | P17861 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | GSTO1 | P78417 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | HPGD | P15428 | 5/20 | 0.47 |
| ▸ | TP53 | P04637 | 5/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.47 |
| ▸ | MAOA | P21397 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13445691 | 0.89 | KMT2A (0.80) | KMT2AMAPTLMNANPC1RAB9A | |
| SCHEMBL15395297 | 0.86 | HTT (0.76) | KMT2AMAPTLMNANPC1RAB9A | |
| SCHEMBL2874820 | 0.85 | MAPT (0.74) | KMT2AMAPTLMNANPC1RAB9A | |
| SCHEMBL15395253 | 0.83 | KMT2A (0.71) | KMT2AMAPTLMNANPC1RAB9A | |
| SCHEMBL2874541 | 0.83 | MAPT (0.71) | KMT2AMAPTLMNANPC1RAB9A | |
| SCHEMBL13066079 | 0.81 | MAPT (0.67) | KMT2AMAPTLMNANPC1RAB9A | |
| SCHEMBL15395350 | 0.73 | MAPT (0.57) | KMT2AMAPTLMNANPC1RAB9A | |
| SCHEMBL2874680 | 0.72 | NPC1 (0.56) | KMT2AMAPTLMNANPC1RAB9A | |
| SCHEMBL2877868 | 0.71 | NPC1 (0.55) | KMT2AMAPTLMNANPC1RAB9A | |
| SCHEMBL22738310 | 0.71 | MEN1 (0.75) | KMT2AMAPTLMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11413267-B2 | Methods and compositions for inhibition of ATR and FANCD2 activation | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2022-08-16 | — | — | US | disclosed |
| US-20190255012-A1 | Methods and Compositions for Inhibition of ATR and FANCD2 Activation | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2019-08-22 | — | — | US | disclosed |
| US-10195176-B2 | Methods and compositions for inhibition of ATR and FANCD2 activation | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2019-02-05 | — | — | US | disclosed |
| US-20180161303-A1 | Methods and Compositions for Inhibition of ATR and FANCD2 Activation | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2018-06-14 | — | — | US | disclosed |
| US-20180161303-A1 | Methods and Compositions for Inhibition of ATR and FANCD2 Activation | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2018-06-14 | — | — | US | disclosed |
| US-9918962-B2 | Methods and compositions for inhibition of ATR and FANCD2 activation | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2018-03-20 | — | — | US | disclosed |
| US-9918962-B2 | Methods and compositions for inhibition of ATR and FANCD2 activation | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2018-03-20 | — | — | US | disclosed |
| US-20160158190-A1 | Methods and Compositions for Inhibition of ATR and FANCD2 Activation | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2016-06-09 | — | — | US | disclosed |
| US-20160158190-A1 | Methods and Compositions for Inhibition of ATR and FANCD2 Activation | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2016-06-09 | — | — | US | disclosed |
| US-20130310448-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF ATR AND FANCD2 ACTIVATION | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2013-11-21 | — | — | US | disclosed |
| US-7842721-B2 | Composition for treating cancer cells and synthetic method for the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2010-11-30 | — | — | US | disclosed |
| US-20100062078-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER AND THE SIGNALING PATHWAY THEREOF | Yuan, Shyng-Shiou (TW) | 2010-03-11 | — | — | US | disclosed |
| US-20100062078-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER AND THE SIGNALING PATHWAY THEREOF | Yuan, Shyng-Shiou (TW) | 2010-03-11 | — | — | US | disclosed |
| US-20090054516-A1 | COMPOSITION FOR TREATING CANCER CELLS AND SYNTHETIC METHOD FOR THE SAME | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2009-02-26 | — | — | US | disclosed |
| EP-1980248-A1 | Composition for treating cancer cells and synthetic method for the same | Kaohsiung Medical University (TW) | 2008-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158190-A1 | Methods and Compositions for Inhibition of ATR and FANCD2 Activation | FANCD2, ATR, FANCF | KMT2A 1132/4885MAPT 2905/4885LMNA 1281/4885 |
| US-20130310448-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF ATR AND FANCD2 ACTIVATION | ATR, FANCD2, CHEK2 | KMT2A 1048/4885MAPT 3776/4885LMNA 1248/4885 |
| US-20180161303-A1 | Methods and Compositions for Inhibition of ATR and FANCD2 Activation | FANCD2, ATR, FANCF | KMT2A 1132/4885MAPT 2905/4885LMNA 1281/4885 |
| US-20190255012-A1 | Methods and Compositions for Inhibition of ATR and FANCD2 Activation | FANCD2, ATR, FANCF | KMT2A 1127/4885MAPT 2892/4885LMNA 1267/4885 |
| US-20100062078-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER AND THE SIGNALING PATHWAY THEREOF | MAPK3, CASP3, MAPK4 | KMT2A 3972/4885MAPT 1999/4885LMNA 2064/4885 |
| US-11413267-B2 | Methods and compositions for inhibition of ATR and FANCD2 activation | FANCD2, ATR, FANCF | KMT2A 1127/4885MAPT 2892/4885LMNA 1267/4885 |
| US-10195176-B2 | Methods and compositions for inhibition of ATR and FANCD2 activation | FANCD2, ATR, FANCF | KMT2A 1132/4885MAPT 2905/4885LMNA 1281/4885 |
| US-20090054516-A1 | COMPOSITION FOR TREATING CANCER CELLS AND SYNTHETIC METHOD FOR THE SAME | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HK2, HCCS | KMT2A 1857/4885MAPT 4770/4885LMNA 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.